Boehringer bets $2B in biobucks to unlock siRNA targets for NASH treatments

Boehringer Ingelheim is having another crack at using RNA to treat nonalcoholic steatohepatitis (NASH). Six years after inking deals for a pair of prospects, the German drugmaker has committed more than $2 billion in biobucks to enter into a multi-target pact with a Chinese biotech and its Swedish subsidiary.